Senti Biosciences is trading 5.9% lower at $0.31, with a potential resale-share overhang weighing on shares. - Its September 25 prospectus registers up to 25,555,024 shares for resale by existing securityholders; the shares are tied to convertible notes, and Senti receives no proceeds from subsequent sales. - No new company announcement explaining the September 28 move was found. - Reuters reported oil rose and Treasury yields climbed after President Trump rejected Iran’s proposal, weighing on U.S. equity futures. The supplied market context showed major indices down.